WebSep 25, 2024 · Galecto is currently conducting a Phase 2b trial of GB0139 in IPF and intends to initiate Phase 2 studies of GB1211 in liver fibrosis related to Non-Alcoholic SteatoHepatitis (NASH) and GB2064 in ... WebApr 26, 2024 · The study is designed to investigate the safety and efficacy of Galecto’s most advanced compound, GB0139, in 141 patients with IPF. Patients in GALACTIC-1 …
Galecto to Present Two Posters at AACR Annual Meeting 2024
WebSep 25, 2024 · Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials; Boston, MA/Copenhagen, Denmark, September 25, 2024 – Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the … WebAug 8, 2024 · Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute lung injury (ALI) remains unknown. Effective pharmacological therapies available for ALI are limited; identifying novel concepts in treatment is essential. GB0139 is a Gal-3 inhibitor currently under clinical investigation for the treatment of … dying process final hours
Galecto
WebMar 15, 2024 · GALACTIC-1 is a 52-week randomized, double-blind, multicenter, parallel, placebo-controlled Phase 2b study being conducted across more than 100 centers globally, investigating the safety and ... GB0139 significantly reduced oxygen flow requirements and improved several biomarkers for lung and systemic inflammation, liver function, tissue damage and coagulation; Data demonstrate potential of GB0139 in patients with viral-induced acute lung injury; Currently Galecto will prioritize resources for its four phase 2 trials in fibrosis and cancer WebApr 27, 2024 · Galecto has concluded subject enrolment in the Phase IIb GALACTIC-1 clinical trial of GB0139 to treat idiopathic pulmonary fibrosis (IPF). The company anticipates topline results from the trial in the middle of next year. The double-blind, randomised, placebo-controlled, parallel-group, multicentre trial is being carried out at nearly 100 sites … dying popcorn